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Pulmonary Medicine deals with the diseases of the respiratory tract and respiratory disease. It is called chest medicine and 
respiratory medicine in some countries and areas. Pulmonology is 
generally considered a branch of internal medicine. Chest medicine 
is not a specialty in itself but is an inclusive term which pertains to 
the treatment of diseases of the chest and contains the fi elds of 
pulmonology, thoracic surgery, and intensive care medicine. Effective 
disease treatment physician specializing in this area are called 
Pulmonologists.
The Journal of Pulmonary & Respiratory Medicine under open 
access category aims to advance our understanding of the diagnosis 
and treatment of lung diseases, as well as secondary prevention 
(Tuberculosis). The Journal of Pulmonary & Respiratory Medicine 
is an international, peer-reviewed journal, publishing an overview of 
Pulmonary Medicine which includes the contents geared towards the 
fi elds of pulmonology, thoracic surgery, and intensive care medicine.
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It is becoming increasingly evident that pulmonary macrophage 
dysfunction contributes to disease pathogenesis in a variety of chronic 
lung diseases including chronic obstructive pulmonary disease 
(COPD) [1], bronchiolitis obliterans syndrome (BOS) following lung 
transplantation [2], cystic fibrosis (CF) [3] and severe asthma (NEA) 
[4]. An abnormal accumulation of apoptotic bronchial epithelial cells 
with an associated defect in the phagocytic ability of neighboring 
macrophages (efferocytosis) can lead to secondary necrosis of the 
uncleared apoptotic material with pro-inflammatory effects [5,6]. 
Specific therapeutic targeting of the macrophage dysfunction is being 
increasingly studied. The actual progression of this strategy to clinical 
use is however still very much in the early stages and much of our 
knowledge of the potential impact of macrophage-targeted therapies 
has evolved in retrospect rather than from a direct developmental 
approach. 
The emerging body of evidence suggests that that the use of long-
term macrolide therapy is both feasible and may offer useful clinical 
outcomes in chronic lung diseases, including COPD, BOS and NEA [6-
8], while results in CF have been inconclusive [9,10]. The mechanism 
of action of macrolides in this regard may be through their effects on 
macrophage function [6-8]. In a small uncontrolled study using low-
dose azithromycin in COPD subjects the principal findings were a 
significant increase in the efferocytosis capacity of alveolar macrophages 
and a reduction in the percentage of apoptotic airway epithelial cells 
obtained by airway brushing [7]. A role for phosphatidyserine (PS) in 
these effects was shown [8]. 
Pulmonary macrophages may contribute to the relative insensitivity 
to cortocosteroids in chronic lung diseases [11,12]. Dexamethasone has 
been shown to improve efferocytosis [13] while in patients with severe 
asthma, defective efferocytosis was improved after a course of high dose 
steroids [14]. In COPD, lung macrophages have reduced expression of 
the epigenetic modifying enzyme histone deacetylase 2 (HDAC2) and 
this is associated with increased expression of inflammatory genes and 
also resistance to corticosteroids [12]. 
Statins also have been shown to improve macrophage phagocytic 
function mediated in part by their inhibitory effects on RhoA [15]. 
In COPD, there is evidence of an improved mortality rate following 
treatment with statins [16]; however, whether the effects of statins 
on macrophage function will translate to human clinical benefit is 
uncertain, as the doses used to achieve the in vitro effects were higher 
than those typically used clinically.
The process of efferocytosis involves signaling through macrophage 
surface receptors that include MER tyrosine kinase (MERTK), GAS6, 
milk fat globule epidermal growth factor 8 (MFG-E8) and several 
putative PS receptors including a G protein-coupled receptor, BAI1 
(brain-specific angiogenes 1), TIM-1 and TIM-4. Activation of protein 
kinase C βII is required for efferocytosis. Scavenger receptors (mannose 
receptor, SRA11 (type AII), MARCO (class A) CD36 (class B)) facilitate 
the phagocytosis of modified protein on apoptotic cells. Dysregulated 
expression of macrophage receptors in COPD has been reported 
[6,7,17-19] and these may provide suitable targets for macrophage-
targeted therapies. Whether epigenetic regulation of the various 
receptors alters their ligand-binding properties also remains unclear, 
and there is a need for characterizing epigenetic signatures of relevant 
genes in macrophages isolated from the various patient groups. 
More recently, strategies are being pursued that are more specifically 
directed towards macrophage function, such as the use of mannose-
binding lectin (MBL). MBL plays a key role in regulating efferocytosis 
and it is expressed at reduced levels in the airway in COPD or BOS 
[2,20]. Human and animal studies support the potential role for MBL 
in improving phagocytosis and reducing inflammation as a therapeutic 
strategy for airways disease [20]. Further studies using anti-oxidants 
with a resultant improvement in macrophage function in smoke 
exposed mice have also been reported [21].
Compelling evidence is thus emerging for the role of defective 
pulmonary macrophage function in the pathogenesis of chronic 
inflammatory airways diseases, and it is also becoming clear that several 
therapies with established clinical efficacy for various conditions may be 
exerting some of their beneficial effects via modulation of macrophage 
function. Greater understanding of the clinical consequences of 
defective macrophage function and its modulation by therapeutic 
agents will progress the development of specific macrophage-targeted 
therapies with complementary or synergistic benefits to established 
therapies.
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